Salidroside inhibits migration and invasion of poorly differentiated thyroid cancer cells

Thorac Cancer. 2019 Jun;10(6):1469-1478. doi: 10.1111/1759-7714.13096. Epub 2019 May 23.

Abstract

Background: No effective treatment is currently available for poorly differentiated thyroid cancer which is resistant to radioiodine, especially with migration and invasion. A great number of researches have revealed the anticancer effects of salidroside, but none have studied the effects of salidroside on thyroid cancer. This study aimed to investigate the effect of salidroside on migration and invasion of poorly differentiated thyroid cancer cells.

Methods: The effects of salidroside on migration, invasion and apoptosis of poorly differentiated thyroid cancer WRO cells and normal thyroid follicular epithelial Nthy-ori 3-1 cells were measured by wound-healing assay, transwell migration/invasion assay and flow cytometry, respectively. The expression levels of MMP2 and MMP9 at RNA and protein levels in WRO cells were detected by qRT-PCR and western blot. The phosphorylation levels of Janus kinase 2 (JAK2), signal transducer and activator of transcription 3 (STAT3) and the apoptosis-related protein levels of Bax, cleaved caspase 3 and Bcl-2 were assessed by western blot.

Results: Salidroside significantly suppressed migration/invasion and induced apoptosis in poorly differentiated thyroid cancer WRO cells. We further illustrated that salidroside significantly inhibited expressions of MMP2 and MMP9 at mRNA and protein levels and the phosphorylation activation of JAK2/STAT3 in WRO cells. In addition, salidroside increased expressions of pro-apoptotic factors (Bax and cleaved caspase 3) and decreased expression of anti-apoptotic factor (Bcl-2) significantly in WRO cells.

Conclusion: The present study demonstrates that salidroside inhibits migration and invasion of WRO cells (a kind of poorly differentiated cancer cell line) significantly, which might be via suppressing JAK2-STAT3 signaling pathway.

Keywords: Invasion; migration; poorly differentiated thyroid cancer; salidroside.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Cell Survival
  • Gene Expression Regulation, Neoplastic / drug effects
  • Glucosides / pharmacology*
  • Humans
  • Janus Kinase 2 / metabolism
  • Matrix Metalloproteinase 2 / genetics
  • Matrix Metalloproteinase 2 / metabolism
  • Matrix Metalloproteinase 9 / genetics
  • Matrix Metalloproteinase 9 / metabolism
  • Phenols / pharmacology*
  • Phosphorylation / drug effects
  • STAT3 Transcription Factor / metabolism
  • Signal Transduction / drug effects*
  • Thyroid Neoplasms / drug therapy
  • Thyroid Neoplasms / genetics
  • Thyroid Neoplasms / metabolism*

Substances

  • Glucosides
  • Phenols
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • JAK2 protein, human
  • Janus Kinase 2
  • MMP2 protein, human
  • Matrix Metalloproteinase 2
  • MMP9 protein, human
  • Matrix Metalloproteinase 9
  • rhodioloside